Press Releases

Month Year

Get News Alerts by Email

Nov 11, 2021

Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference

Consistency of Efficacy Assessments Evaluated Across Various Statistical Methods

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...
Nov 10, 2021

Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On Alzheimer's Disease (CTAD) Conference

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...
Nov 8, 2021

DIAN-TU Selects Lecanemab As Background Anti-Amyloid Therapy In Clinical Trial Evaluating Investigational Therapy Targeting Tau For Dominantly Inherited Alzheimer's Disease

Eisai's anti-microtubule binding region (MTBR) tau antibody E2814 previously selected as the first investigational therapy among anti-tau drugs for the DIAN-TU Tau Next Generation trial

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of...
Nov 4, 2021

Eisai Presents New Data on the Relationship between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2b Study for Early Alzheimer's disease in Late-Breakers and Pipeline Updates at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of data from the company's extensive Alzheimer's disease (AD) pipeline, including six oral...
Sep 27, 2021

Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway

Lecanemab Is An Anti-Amyloid Beta (Aβ) Protofibril Antibody

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...

Show per page

Open a printable version of this page
Email the URL of this page to a friend